Archive · 6 Aug 2025
Intas Pharmaceuticals Launches Novel Lung Cancer Immunotherapy in India
Imagine a new medicine, HETRONIFLY™, is now available in India to fight a type of lung cancer.
This medicine is like a super-powered immune system helper, and it's the first of its kind in the world for this specific cancer.
It works better than the old way of treating the cancer, called chemotherapy, by helping patients live longer.
The new medicine is also much cheaper than other similar medicines, which makes it easier for people in India to get the treatment they need.
Intas Pharmaceuticals launched HETRONIFLY™ (Serplulimab) in India, a PD-1 inhibitor for advanced Small Cell Lung Cancer.
This launch follows a licensing agreement with Shanghai Henlius Biotech, Inc.
Serplulimab is the first PD-1 inhibitor approved worldwide for Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
The drug demonstrated a 40% reduction in the risk of death compared to the standard-of-care chemotherapy.
HETRONIFLY™ is priced approximately 75% lower than existing immunotherapies for this condition in India.
- Who
- Intas Pharmaceuticals
- What
- Intas Pharmaceuticals launched HETRONIFLY™ (Serplulimab), a PD-1 inhibitor for advanced Small Cell Lung Cancer.
- When
- August 6
- Where
- India
- Why
- To provide an effective and affordable treatment option for patients with advanced Small Cell Lung Cancer.
Benefits of Serplulimab
N/A
Efficacy
Benefits of Serplulimab
Improved survival rates and reduced risk of death.
N/A
N/A
Affordability
Benefits of Serplulimab
Significantly lower cost compared to other immunotherapies.
N/A
N/A
- Drug Name
- HETRONIFLY™ (Serplulimab)
- Indication
- Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
- Manufacturer
- Intas Pharmaceuticals
- Approval
- First PD-1 inhibitor globally approved for ES-SCLC in India
- Cost
- Approximately 75% lower than other immunotherapies
- Clinical Trial Result
- 40% reduction in the risk of death compared to standard chemotherapy